Beigel JH. Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis. 2018 Oct 5.
PURPOSE OF REVIEW:
This review summarizes past and ongoing efforts for using polyclonal and monoclonal antibodies for the treatment of influenza, and is focused on products that have entered clinical trials.
RECENT FINDINGS:
At least 3 polyclonal and 8 monoclonal antibody products have been tested in clinical trials for the treatment of influenza. Considered across the two classes of therapeutics, these products appear to be safe and well tolerated. However, the efficacy results have been mixed and inconclusive. To date, no products have consistently shown superiority to currently available antivirals.
SUMMARY:
No products within these two classes have been licensed, and several products appear to have stopped further clinical development. There are several ongoing studies that are anticipated to be completed or reported in the next 1-2 years which will be critical for understanding the value of polyclonal and monoclonal antibodies in the treatment of influenza.
This review summarizes past and ongoing efforts for using polyclonal and monoclonal antibodies for the treatment of influenza, and is focused on products that have entered clinical trials.
RECENT FINDINGS:
At least 3 polyclonal and 8 monoclonal antibody products have been tested in clinical trials for the treatment of influenza. Considered across the two classes of therapeutics, these products appear to be safe and well tolerated. However, the efficacy results have been mixed and inconclusive. To date, no products have consistently shown superiority to currently available antivirals.
SUMMARY:
No products within these two classes have been licensed, and several products appear to have stopped further clinical development. There are several ongoing studies that are anticipated to be completed or reported in the next 1-2 years which will be critical for understanding the value of polyclonal and monoclonal antibodies in the treatment of influenza.
See Also:
Latest articles in those days:
- High-throughput pseudovirus neutralisation maps the antigenic landscape of influenza A/H1N1 viruses 22 hours ago
- Timely vaccine strain selection and genomic surveillance improve evolutionary forecast accuracy of seasonal influenza A/H3N2 22 hours ago
- Evaluation of a Novel Data Source for National Influenza Surveillance: Influenza Hospitalization Data in the National Healthcare Safety Network, United States, September 2021-April 2024 22 hours ago
- Scenarios for pre-pandemic zoonotic influenza preparedness and response 22 hours ago
- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk 2 days ago
[Go Top] [Close Window]
